234 related articles for article (PubMed ID: 35414272)
21. Feasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses.
Nimri R; Grosman B; Roy A; Nir J; Fisch Shvalb N; Kurtz N; Loewenthal N; Gillon-Keren M; Muller I; Atlas E; Phillip M
Diabetes Technol Ther; 2021 Apr; 23(4):268-276. PubMed ID: 33185480
[No Abstract] [Full Text] [Related]
22. Long-term effectiveness of advanced hybrid closed loop in children and adolescents with type 1 diabetes.
Piccini B; Pessina B; Casalini E; Lenzi L; Toni S
Pediatr Diabetes; 2022 Dec; 23(8):1647-1655. PubMed ID: 36317539
[TBL] [Abstract][Full Text] [Related]
23. A comparison of the usage of an open-source automated insulin delivery system and the MiniMed™ 780 G system in children and adolescents with type 1 diabetes in real-world settings: the AWeSoMe study group.
Landau Z; Lebenthal Y; Mazor-Aronovitch K; Brener A; Levek N; Jacobi-Polishook T; Ben Ari T; Abiri S; Haim A; Nir J; Rachmiel M; Pinhas-Hamiel O
Endocrine; 2024 Jun; 84(3):943-950. PubMed ID: 38225516
[TBL] [Abstract][Full Text] [Related]
24. Glycemic control metrics in a cohort of hospitalized patients with type 1 diabetes using hybrid closed-loop and advanced hybrid closed-loop systems.
Gómez Medina AM; Henao-Carrillo DC; Yepes C; Silva J; Gómez González JA; Cortes D; Robledo S; Mejía G; Rondon M
Diabetes Res Clin Pract; 2023 Oct; 204():110897. PubMed ID: 37678728
[TBL] [Abstract][Full Text] [Related]
25. Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial.
Garg SK; Grunberger G; Weinstock R; Lawson ML; Hirsch IB; DiMeglio LA; Pop-Busui R; Philis-Tsimikas A; Kipnes M; Liljenquist DR; Brazg RL; Kudva YC; Buckingham BA; McGill JB; Carlson AL; Criego AB; Christiansen MP; Kaiserman KB; Griffin KJ; Forlenza GP; Bode BW; Slover RH; Keiter A; Ling C; Marinos B; Cordero TL; Shin J; Lee SW; Rhinehart AS; Vigersky RA;
Diabetes Technol Ther; 2023 Jan; 25(1):1-12. PubMed ID: 36472543
[No Abstract] [Full Text] [Related]
26. Fast-Acting Insulin Aspart Use with the MiniMed
Hsu L; Buckingham B; Basina M; Ekhlaspour L; von Eyben R; Wang J; Lal RA
Diabetes Technol Ther; 2021 Jan; 23(1):1-7. PubMed ID: 32520594
[No Abstract] [Full Text] [Related]
27. MiniMed 780G Six-Month Use in Children and Adolescents with Type 1 Diabetes: Clinical Targets and Predictors of Optimal Glucose Control.
Lombardo F; Passanisi S; Alibrandi A; Bombaci B; Bonfanti R; Delvecchio M; Di Candia F; Mozzillo E; Piccinno E; Piona CA; Rigamonti A; Scialabba F; Maffeis C; Salzano G
Diabetes Technol Ther; 2023 Jun; 25(6):404-413. PubMed ID: 36763343
[No Abstract] [Full Text] [Related]
28. Ultrarapid Lispro Demonstrates Similar Time in Target Range to Lispro with a Hybrid Closed-Loop System.
Bode B; Carlson A; Liu R; Hardy T; Bergenstal R; Boyd J; Morrett S; Ignaut D
Diabetes Technol Ther; 2021 Dec; 23(12):828-836. PubMed ID: 34270335
[No Abstract] [Full Text] [Related]
29. Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes.
Akturk HK; Giordano D; Champakanath A; Brackett S; Garg S; Snell-Bergeon J
Diabetes Obes Metab; 2020 Apr; 22(4):583-589. PubMed ID: 31789447
[TBL] [Abstract][Full Text] [Related]
30. Prospective Analysis of the Impact of Commercialized Hybrid Closed-Loop System on Glycemic Control, Glycemic Variability, and Patient-Related Outcomes in Children and Adults: A Focus on Superiority Over Predictive Low-Glucose Suspend Technology.
Beato-Víbora PI; Gallego-Gamero F; Lázaro-Martín L; Romero-Pérez MDM; Arroyo-Díez FJ
Diabetes Technol Ther; 2020 Dec; 22(12):912-919. PubMed ID: 31855446
[No Abstract] [Full Text] [Related]
31. Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations.
Forlenza GP; Carlson AL; Galindo RJ; Kruger DF; Levy CJ; McGill JB; Umpierrez G; Aleppo G
Diabetes Technol Ther; 2022 Nov; 24(11):814-823. PubMed ID: 35763323
[No Abstract] [Full Text] [Related]
32. Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review.
Mameli C; Smylie GM; Galati A; Rapone B; Cardona-Hernandez R; Zuccotti G; Delvecchio M
Eur J Pediatr; 2023 May; 182(5):1949-1963. PubMed ID: 36809498
[TBL] [Abstract][Full Text] [Related]
33. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.
Bergenstal RM; Nimri R; Beck RW; Criego A; Laffel L; Schatz D; Battelino T; Danne T; Weinzimer SA; Sibayan J; Johnson ML; Bailey RJ; Calhoun P; Carlson A; Isganaitis E; Bello R; Albanese-O'Neill A; Dovc K; Biester T; Weyman K; Hood K; Phillip M;
Lancet; 2021 Jan; 397(10270):208-219. PubMed ID: 33453783
[TBL] [Abstract][Full Text] [Related]
34. One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes.
Petrovski G; Al Khalaf F; Campbell J; Umer F; Almajaly D; Hamdan M; Hussain K
Acta Diabetol; 2021 Feb; 58(2):207-213. PubMed ID: 33044604
[TBL] [Abstract][Full Text] [Related]
35. Efficacy, Safety, and Satisfaction with the Accu-Chek Insight with Diabeloop Closed-Loop System in Subjects with Type 1 Diabetes: A Multicenter Real-World Study.
Chico A; Navas de Solís S; Lainez M; Rius F; Cuesta M
Diabetes Technol Ther; 2023 Apr; 25(4):242-249. PubMed ID: 36724301
[No Abstract] [Full Text] [Related]
36. Increased proportion of time in hybrid closed-loop "Auto Mode" is associated with improved glycaemic control for adolescent and young patients with adult type 1 diabetes using the MiniMed 670G insulin pump.
Duffus SH; Ta'ani ZA; Slaughter JC; Niswender KD; Gregory JM
Diabetes Obes Metab; 2020 Apr; 22(4):688-693. PubMed ID: 31709736
[TBL] [Abstract][Full Text] [Related]
37. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes.
Garg SK; Weinzimer SA; Tamborlane WV; Buckingham BA; Bode BW; Bailey TS; Brazg RL; Ilany J; Slover RH; Anderson SM; Bergenstal RM; Grosman B; Roy A; Cordero TL; Shin J; Lee SW; Kaufman FR
Diabetes Technol Ther; 2017 Mar; 19(3):155-163. PubMed ID: 28134564
[TBL] [Abstract][Full Text] [Related]
38. Glycemic Effects and Predictors of Increased Time-in-Range After Initiating MiniMed 670G: A 12-Month Observational Study.
Jacobsen SS; Hommel E; Ranjan AG; Nørgaard K
Diabetes Technol Ther; 2022 Aug; 24(8):592-597. PubMed ID: 35099298
[TBL] [Abstract][Full Text] [Related]
39. REAL-WORLD IMPLICATIONS OF HYBRID CLOSE LOOP (HCL) INSULIN DELIVERY SYSTEM.
Faulds ER; Zappe J; Dungan KM
Endocr Pract; 2019 May; 25(5):477-484. PubMed ID: 30865545
[No Abstract] [Full Text] [Related]
40. Glycemic control in people with type 1 diabetes using a hybrid closed loop system and followed by telemedicine during the COVID-19 pandemic in Italy.
Longo M; Caruso P; Petrizzo M; Castaldo F; Sarnataro A; Gicchino M; Bellastella G; Esposito K; Maiorino MI
Diabetes Res Clin Pract; 2020 Nov; 169():108440. PubMed ID: 32926958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
